BRCA1 and breast carcinoma: After eliminating these types of bias, Heemskerk-Gerritsen et al. did not find breast cancer risk reduction post-RRSO (HR: 1.09, 95% CI: 0.67–1.77) in 822 Dutch BRCA1/2 GPV carriers [10].